Outcomes and endpoints of relevance in gynecologic cancer clinical trials

Ainhoa Madariaga(Hospital Universitario 12 De Octubre), Antonio González-Martı́n(Spanish Ovarian Cancer Research Group), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Fernanda Herrera(Centre Hospitalier Universitaire Vaudois), Pedro T. Ramírez(Houston Methodist)
International Journal of Gynecological Cancer
March 1, 2023
10.1136/ijgc-2022-003727
Cited by 11

Related Papers

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2013|1.1k